Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy, which just became the priciest medicine in the US
Roche could pay $5 billion for biotech company Spark Therapeutics. The pharma giant likely wants to expand its presence in hemophilia, a lucrative market.
